MA32288B1 - Nouveaux anticorps utiles pour le traitement du cancer - Google Patents
Nouveaux anticorps utiles pour le traitement du cancerInfo
- Publication number
- MA32288B1 MA32288B1 MA33315A MA33315A MA32288B1 MA 32288 B1 MA32288 B1 MA 32288B1 MA 33315 A MA33315 A MA 33315A MA 33315 A MA33315 A MA 33315A MA 32288 B1 MA32288 B1 MA 32288B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- relates
- cancer treatment
- antibodies useful
- new antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention est relative à de nouveaux anticorps capables de se lier spécifiquement à la protéine humaine cd 151, notamment monoclonaux d'origine murine, chimériques et humanisés, ainsi que les séquences d'acide aminé et nucléiques codant pour ces anticorps. L'invention comprend également l'utilisation de ces anticorps à titre de médicament pour le traitement prophylactique et/ou thérapeutique de cancers ainsi que dans des procédés ou nécessaire de diagnostic de maladies liées à la surexpression de la protéine cd151. L'invention comprend enfin des produits et/ou des compositions comprenant de tels anticorps en association avec des anticorps et/ou des agents anticancéreux ou conjugués avec des toxines et./ou des radioéléments et leur utilisation pour la prévention et/ou le traitement de certains cancers.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0801985A FR2929946B1 (fr) | 2008-04-11 | 2008-04-11 | Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer |
PCT/FR2009/050612 WO2009136070A1 (fr) | 2008-04-11 | 2009-04-08 | Nouveaux anticorps utiles pour le traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32288B1 true MA32288B1 (fr) | 2011-05-02 |
Family
ID=39645493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33315A MA32288B1 (fr) | 2008-04-11 | 2010-11-03 | Nouveaux anticorps utiles pour le traitement du cancer |
Country Status (23)
Country | Link |
---|---|
US (3) | US8198413B2 (fr) |
EP (1) | EP2268671A1 (fr) |
JP (1) | JP2011517565A (fr) |
KR (1) | KR20110010708A (fr) |
CN (1) | CN102027014A (fr) |
AR (1) | AR071304A1 (fr) |
AU (1) | AU2009245587B2 (fr) |
BR (1) | BRPI0909016A2 (fr) |
CA (1) | CA2720904A1 (fr) |
CL (1) | CL2009000862A1 (fr) |
CO (1) | CO6311009A2 (fr) |
FR (1) | FR2929946B1 (fr) |
GE (1) | GEP20135826B (fr) |
IL (1) | IL208595A0 (fr) |
MA (1) | MA32288B1 (fr) |
MX (1) | MX2010011147A (fr) |
NZ (1) | NZ588887A (fr) |
RU (1) | RU2010145063A (fr) |
SA (1) | SA109300216B1 (fr) |
TW (1) | TW201002347A (fr) |
UA (1) | UA105630C2 (fr) |
WO (1) | WO2009136070A1 (fr) |
ZA (1) | ZA201007751B (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2907341B1 (fr) * | 2006-10-18 | 2012-08-17 | Pf Medicament | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
FR2929519B1 (fr) * | 2008-04-04 | 2010-04-23 | Pf Medicament | Utilisation d'un anticorps anti-cd151 pour le traitement precoce des cancers. |
EP2308897A1 (fr) * | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Anticorps chimères spécifiques de CD151 et leurs utilisations pour le traitement du cancer |
CA2827007A1 (fr) * | 2011-02-11 | 2012-08-16 | Research Corporation Technologies, Inc. | Molecules de matrice a domaine ch2 issues de la greffe rationnelle de boucles de donneur sur des echafaudages ch2 |
WO2012131680A2 (fr) | 2011-03-28 | 2012-10-04 | Yeda Research And Development Co. Ltd. | Compositions et procédés pour le traitement de l'inflammation |
FR3017936B1 (fr) | 2014-02-21 | 2019-03-15 | Thales | Systeme de regulation thermique d'au moins un module electronique embarque a bord d'un aeronef |
JP2019500893A (ja) * | 2015-11-03 | 2019-01-17 | ヤンセン バイオテツク,インコーポレーテツド | Pd−1及びtim−3に特異的に結合する抗体及びそれらの使用 |
ITUB20154769A1 (it) * | 2015-11-04 | 2017-05-04 | Centro Di Riferimento Oncologico Cro Irccs Aviano | Anticorpo monoclonale anti-BARF1 |
AU2019236091A1 (en) | 2018-03-13 | 2020-09-03 | Phanes Therapeutics, Inc. | Anti-folate receptor 1 antibodies and uses thereof |
CA3115077A1 (fr) * | 2018-10-09 | 2020-04-16 | Ibex Biosciences, Llc | Anticorps diriges contre la filamine-a et leurs utilisations therapeutiques |
WO2023235666A2 (fr) * | 2022-05-31 | 2023-12-07 | Vanderbilt University | Anticorps humains contre bordetella pertussis et leurs utilisations |
CN114790240B (zh) * | 2022-06-10 | 2023-06-06 | 郑州大学 | SARS-CoV-2中和性单克隆抗体及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4441799A (en) * | 1998-06-15 | 2000-01-05 | Research Foundation Of The State University Of New York, The | Monoclonal antibodies that recognize antigens associated with tumor metastasis |
US20070054278A1 (en) * | 2003-11-18 | 2007-03-08 | Applera Corporation | Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof |
US20080003605A1 (en) * | 2006-05-24 | 2008-01-03 | The University Of Chicago | Microarray analysis of light chain variable gene expression and methods of use |
FR2907341B1 (fr) * | 2006-10-18 | 2012-08-17 | Pf Medicament | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
-
2008
- 2008-04-11 FR FR0801985A patent/FR2929946B1/fr not_active Expired - Fee Related
-
2009
- 2009-04-08 BR BRPI0909016A patent/BRPI0909016A2/pt not_active IP Right Cessation
- 2009-04-08 CN CN2009801169974A patent/CN102027014A/zh active Pending
- 2009-04-08 KR KR1020107024503A patent/KR20110010708A/ko not_active Application Discontinuation
- 2009-04-08 GE GEAP200911995A patent/GEP20135826B/en unknown
- 2009-04-08 WO PCT/FR2009/050612 patent/WO2009136070A1/fr active Application Filing
- 2009-04-08 JP JP2011503478A patent/JP2011517565A/ja active Pending
- 2009-04-08 RU RU2010145063/10A patent/RU2010145063A/ru not_active Application Discontinuation
- 2009-04-08 AU AU2009245587A patent/AU2009245587B2/en not_active Expired - Fee Related
- 2009-04-08 AR ARP090101245A patent/AR071304A1/es unknown
- 2009-04-08 MX MX2010011147A patent/MX2010011147A/es active IP Right Grant
- 2009-04-08 EP EP09742268A patent/EP2268671A1/fr not_active Withdrawn
- 2009-04-08 SA SA109300216A patent/SA109300216B1/ar unknown
- 2009-04-08 CA CA2720904A patent/CA2720904A1/fr not_active Abandoned
- 2009-04-08 NZ NZ588887A patent/NZ588887A/xx not_active IP Right Cessation
- 2009-04-08 UA UAA201013336A patent/UA105630C2/uk unknown
- 2009-04-09 CL CL2009000862A patent/CL2009000862A1/es unknown
- 2009-04-10 TW TW098111908A patent/TW201002347A/zh unknown
- 2009-10-09 US US12/576,824 patent/US8198413B2/en not_active Expired - Fee Related
-
2010
- 2010-10-10 IL IL208595A patent/IL208595A0/en unknown
- 2010-10-29 ZA ZA2010/07751A patent/ZA201007751B/en unknown
- 2010-11-03 MA MA33315A patent/MA32288B1/fr unknown
- 2010-11-11 CO CO10141712A patent/CO6311009A2/es active IP Right Grant
-
2012
- 2012-04-05 US US13/440,259 patent/US8697855B2/en not_active Expired - Fee Related
-
2013
- 2013-10-09 US US14/049,617 patent/US20140193329A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100150902A1 (en) | 2010-06-17 |
IL208595A0 (en) | 2010-12-30 |
SA109300216B1 (ar) | 2013-04-20 |
JP2011517565A (ja) | 2011-06-16 |
TW201002347A (en) | 2010-01-16 |
CA2720904A1 (fr) | 2009-11-12 |
AU2009245587A1 (en) | 2009-11-12 |
FR2929946B1 (fr) | 2010-05-28 |
US20120284810A1 (en) | 2012-11-08 |
US8697855B2 (en) | 2014-04-15 |
AR071304A1 (es) | 2010-06-09 |
US20140193329A1 (en) | 2014-07-10 |
KR20110010708A (ko) | 2011-02-07 |
MX2010011147A (es) | 2011-10-10 |
CN102027014A (zh) | 2011-04-20 |
BRPI0909016A2 (pt) | 2015-12-22 |
CO6311009A2 (es) | 2011-08-22 |
UA105630C2 (uk) | 2014-06-10 |
WO2009136070A1 (fr) | 2009-11-12 |
NZ588887A (en) | 2012-10-26 |
ZA201007751B (en) | 2011-08-31 |
EP2268671A1 (fr) | 2011-01-05 |
RU2010145063A (ru) | 2012-05-20 |
CL2009000862A1 (es) | 2009-08-14 |
FR2929946A1 (fr) | 2009-10-16 |
US8198413B2 (en) | 2012-06-12 |
GEP20135826B (en) | 2013-05-27 |
AU2009245587B2 (en) | 2014-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32288B1 (fr) | Nouveaux anticorps utiles pour le traitement du cancer | |
NL301089I2 (nl) | imlifidase | |
UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
CY1119454T1 (el) | Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος | |
TN2014000148A1 (en) | Antigen binding protein and its use as addressing product for the treatment of cancer | |
MX355181B (es) | Anticuerpos humanos contra el factor tisular. | |
UA116874C2 (uk) | Імунокон'югат анти-мезотеліну | |
DK2097453T3 (da) | Monoklonale antistoffer mod humant Anti-Müllerian Hormon type II receptor (AMHR-II) | |
UA95068C2 (uk) | Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування | |
UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
MX353319B (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
CO6612264A2 (es) | Proteinas terapeuticas de la union a dll 4 | |
WO2005103081A3 (fr) | Anticorps monoclonaux humains diriges contre cd20 | |
MX2018010331A (es) | Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos. | |
WO2009083009A3 (fr) | Anticorps monoclonaux anti-cd32b | |
IN2015DN02349A (fr) | ||
MX2013007067A (es) | Anticuerpos anti-il-18 y sus usos. | |
ATE528319T1 (de) | Krebsbehandlung mit anti-il-1-antikörpern | |
MX2021002144A (es) | Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer. | |
UA99601C2 (ru) | Применение антитела к cd151 для лечения первичных опухолей | |
NZ589795A (en) | Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis | |
WO2008042941A3 (fr) | Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse | |
WO2007007152A3 (fr) | Anticorps anti-madcam utilises pour le traitement de cancers metastatiques et du chlorome | |
TN2012000151A1 (en) | Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer | |
UA108207C2 (xx) | Високоафінне людське антитіло до людського ангіопоетину-2 |